Immunohistochemical estimates of angiogenesis, proliferative activity, p53 expression, and multiple drug resistance have no prognostic impact in osteosarcoma: A comparative clinicopathological investigation

Sarcoma

Volumn 2008, Issue , 2008, Pages

  Sorensen, Flemming Brandt ^a   Jensen, Kenneth ^b   Vaeth, Michael ^c   Hager, Henrik ^a   Funder, Anette Mariane Daa ^a   Safwat, Akmal ^b   Keller, Johnny ^b   Christensen, Mariann ^a  

^a University Institute of Pathology Arhus   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD34 ANTIGEN; GLYCOPROTEIN P; KI 67 ANTIGEN; PROTEIN P53;

ADOLESCENT; ADULT; AGED; AMPUTATION; ANGIOGENESIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL PROLIFERATION; CHILD; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; OSTEOSARCOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SCHOOL CHILD;

EID: 62549110360     PISSN: 1357714X     EISSN: 13691643     Source Type: Journal    
DOI: 10.1155/2008/874075     Document Type: Article

References (71)

1. Bentzen S. M., Poulsen H. S., Kaae S., Prognostic factors in osteosarcomas. A regression analysis Cancer 1988 62 1 194 202
2. Taylor W. F., Ivins J. C., Unni K. K., Beabout J. W., Golenzer H. J., Black L. E., Prognostic variables in osteosarcoma: a multi-institutional study Journal of the National Cancer Institute 1989 81 1 21 30
3. Glasser D. B., Lane J. M., Huvos A. G., Marcove R. C., Rosen G., Survival, prognosis, and therapeutic response in osteogenic sarcoma. The memorial hospital experience Cancer 1992 69 3 698 708
4. Bieling P., Rehan N., Winkler P., Tumor size and prognosis in aggressively treated osteosarcoma Journal of Clinical Oncology 1996 14 3 848 858
5. Ferrari S., Bertoni F., Mercuri M., Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: an analysis of 300 patients treated at the Rizzoli Institute Annals of Oncology 2001 12 8 1145 1150
6. Davis A. M., Bell R. S., Goodwin P. J., Prognostic factors in osteosarcoma: a critical review Journal of Clinical Oncology 1994 12 2 423 431
7. Bielack S. S., Kempf-Bielack B., Delling G., Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols Journal of Clinical Oncology 2002 20 3 776 790
8. Salzer-Kunstschik M., Brand G., Delling G., Bestimmung des morphologischen regressionsgrades nach chemotherapie bei malignen knochentumoren Pathologe 1983 4 3 135 141
9. Picci P., Bacci G., Campanacci M., Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy. Regional mapping of viable and nonviable tumor Cancer 1985 56 7 1515 1521
10. Jong R., Davis A. M., Mendes M. G., Wunder J. S., Bell R. S., Kandel R., Proliferative activity (Ki-67 expression) and outcome in high grade osteosarcoma: a study of 27 cases Sarcoma 2000 4 1-2 47 55
11. Gokgoz N., Wunder J. S., Mousses S., Eskandarian S., Bell R. S., Andrulis I. L., Comparison of p53 mutations in patients with localized osteosarcoma and metastatic osteosarcoma Cancer 2001 92 8 2181 2189
12. Baldini N., Scotlandi K., Barbanti-Brdano G., Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome The New England Journal of Medicine 1995 333 21 1380 1385
13. Lewis I. J., Nooij M. A., Whelan J., Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup Journal of the National Cancer Institute 2007 99 2 112 128
14. Mantadakis E., Kim G., Reisch J., Lack of prognostic significance of intratumoral angiogenesis in nonmetastatic osteosarcoma Journal of Pediatric Hematology Oncology 2001 23 5 286 289
15. Wang D., Chen L., Gao F., Correlation of tumor microvesseldensity with prognosis in osteogenic sarcoma Zhonghua Bing Li Xue Za Zhi 1997 26 5 266 269
16. Mikuli D., Ili I., epuli M., Tumor angiogenesis and outcome in osteosarcoma Pediatric Hematology and Oncology 2004 21 7 611 619
17. Kreuter M., Bieker R., Bielaek S. S., Prognostic relevance of increased angiogenesis in osteosarcoma Clinical Cancer Research 2004 10 24 8531 8537
18. Ek E. T., Ojaimi J., Kitagawa Y., Choong P. F., Does the degree of intratumoural microvessel density and VEGF expression have prognostic significance in osteosarcoma? Oncology Reports 2006 16 1 17 23
19. Edmonson J. H., Long H. J., Richardson R. L., Creagan E. T., Green S. J., Phase II study of a combination of mitomycin, doxorubicin and cisplatin in advanced sarcomas Cancer Chemotherapy and Pharmacology 1985 15 2 181 182
20. Beck W. T., Grogan T. M., Willman C. L., Methods to detect P-glycoprotein-associated multidrug resistance in patients tumors: consensus recommendations Cancer Research 1996 56 13 3010 3020
21. Gundersen H. J. G., Notes on the estimation of the numerical density of arbitrary profiles: the edge effect Journal of Microscopy 1977 111 219 233
22. Chalkley H. W., Method for the quantitative morphologic analysis of tissues Journal of the National Cancer Institute 1943 4 47 53
23. Vermeulen P. B., Gasparini G., Fox S. B., Colpaert C., Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours European Journal of Cancer 2002 38 12 1564 1579
24. Vollmer E., Roessner A., Gerdes J., Improved grading of bone tumors with the monoclonal antibody Ki-67 Journal of Cancer Research and Clinical Oncology 1986 112 3 281 282
25. Vollmer E., Roessner A., Wuisman P., Hrle A., Grundmann E., The proliferation behavior of bone tumors investigated with the monoclonal antibody Ki-67 Current Topics in Pathology 1989 80 91 114
26. Park H.-R., Park Y.-K., Expression of p53 protein, PCNA, and Ki-67 in osteosarcomas of bone Journal of Korean Medical Science 1995 10 5 360 367
27. Psl M., Amling M., Werner M., Osteosarkomapoptose und proliferation untersuchung zur bcl-2-expression Der Pathologe 1994 15 6 337 344
28. Stenzel I., Psl M., Ritzel H., Hentz M., Werner M., Delling G., Zellproliferation bei knochentumoren immunhistologische untersuchung zur Ki-67-proteinexpression Der Pathologe 1996 17 1 56 62
29. van Oijen M. G. C. T., Medema R. H., Slootweg P. J., Rijksen G., Positivity of the proliferation marker Ki-67 in noncycling cells American Journal of Clinical Pathology 1998 110 1 24 31
30. Okada K., Nishida J., Morita T., Kakizaki H., Ishikawa A., Hotta T., Low-grade intraosseous osteosarcoma in northern Japan: advantage of AgNOR and MIB-1 staining in differential diagnosis Human Pathology 2000 31 6 633 639
31. Oda Y., Naka T., Takeshita M., Iwamoto Y., Tsuneyoshi M., Comparison of histological changes and changes in nm23 and c-MET expression between primary and metastatic sites in osteosarcoma: a clinicopathologic and immunohistochemical study Human Pathology 2000 31 6 709 716
32. Scotlandi K., Serra M., Manara M. C., Clinical relevance of Ki-67 expression in bone tumors Cancer 1995 75 3 806 814
33. Hernndez-Rodrguez N.A., Correa E., Sotelo R., Ki-67: a proliferative marker that may predict pulmonary metastases and mortality of primary osteosarcoma Cancer Detection and Prevention 2001 25 2 210 215
34. Jensen M. L., Schumacher B., Jensen O. M., Nielsen O. S., Keller J., Extraskeletal osteosarcomas: a clinicopathologic study of 25 cases American Journal of Surgical Pathology 1998 22 5 588 594
35. Stefanou D. G., Nonni A. V., Agnantis N. J., Athanassiadou S. E., Briassoulis E., Pavlidis N., p53/MDM-2 immunohistochemical expression correlated with proliferative activity in different subtypes of human sarcomas: a ten-year follow-up study Anticancer Research 1998 18 6B 4673 4681
36. Wadayama B., Toguchida J., Yamaguchi T., Sasaki M. S., Kotoura Y., Yamamuro T., p53 expression and its relationship to DNA alterations in bone and soft tissue sarcomas British Journal of Cancer 1993 68 6 1134 1139
37. Oda Y., Wehrmann B., Radig K., Expression of growth factors and their receptors in human osteosarcomas. Immunohistochemical detection of epidermal growth factor, platelet-derived growth factor and their receptors: its correlation with proliferating activities and p53 expression General Diagnostic Pathology 1995 141 2 97 103
38. Lonardo F., Ueda T., Huvos A. G., Healey J., Ladanyi M., p53 and MDM2 alterations in osteosarcomas. Correlation with clinicopathologic features and proliferative rate Cancer 1997 79 8 1541 1547
39. Ueda Y., Dockhorn-Dwornizak B., Blasius S., Analysis of mutant P53 protein in osteosarcomas and other malignant and benign lesions of bone Journal of Cancer Research and Clinical Oncology 1993 119 3 172 178
40. Gorlick R., Huvos A. G., Heller G., Expression of HER2/ erb B-2 correlates with survival in osteosarcoma Journal of Clinical Oncology 1999 17 9 2781 2788
41. Naka T., Fukuda T., Shinohara N., Iwamoto Y., Sugioka Y., Tsuneyoshi M., Osteosarcoma versus malignant fibrous histiocytoma of bone in patients older than 40 years. A clinicopathologic and immunohistochemical analysis with special reference to malignant fibrous histiocytoma-like osteosarcoma Cancer 1995 76 6 972 984
42. Hall P. A., Lane D. P., p53 In tumour pathology: can we trust immunohistochemistry?-revisited! The Journal of Pathology 1994 172 1 1 4
43. Goto A., Kanda H., Ishikawa Y., Association of loss of heterozygosity at the p53 locus with chemoresistance in osteosarcomas Japanese Journal of Cancer Research 1998 89 5 539 547
44. Toguchida J., Yamaguchi T., Ritchie B., Mutation spectrum of the p53 gene in bone and soft tissue sarcomas Cancer Research 1992 52 22 6194 6199
45. Radig K., Schneider-Stock R., Haeckel C., Neumann W., Roessner A., p53 gene mutations in osteosarcomas of low-grade malignancy Human Pathology 1998 29 11 1310 1316
46. Walkley C. R., Qudsi R., Sankaran V. G., Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease Genes Development 2008 22 12 1662 1676
47. Miller C. W., Aslo A., Won A., Tan M., Lampkin B., Koeffler H. P., Alterations of the p53, Rb and MDM2 genes in osteosarcoma Journal of Cancer Research and Clinical Oncology 1996 122 9 559 565
48. Kaseta M.-K. A., Khaldi L., Gomatos I. P., Prognostic value of bax, bcl-2, and p53 staining in primary osteosarcoma Journal of Surgical Oncology 2008 97 3 259 266
49. Park Y. B., Kim H. S., Oh J. H., Lee S. H., The co-expression of p53 protein and P-glycoprotein is correlated to a poor prognosis in osteosarcoma International Orthopaedics 2001 24 6 307 310
50. Chan H. S. L., Grogan T. M., Haddad G., DeBoer G., Ling V., P-glycoprotein expression: critical determinant in the response to osteosarcoma chemotherapy Journal of the National Cancer Institute 1997 89 22 1706 1715
51. Radig K., Hackel C., Herting J., Expression of P-glycoprotein in high grade osteosarcomas with special emphasis on chondroblastic subtype General Diagnostic Pathology 1997 142 3-4 139 145
52. Psl M., Amling M., Grahl K., P-glycoprotein expression in high grade central osteosarcoma and normal bone cells. An Immunohistochemical study General Diagnostic Pathology 1997 142 5-6 317 325
53. Serra M., Scotlandi K., Manara M. C., Analysis of P-glycoprotein expression in osteosarcoma European Journal of Cancer 1995 31 12 1998 2002
54. Ferrari S., Bertoni F., Zanella L., Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma Cancer 2004 100 9 1936 1942
55. Kakar S., Mihalov M., Chachlani N. A., Ghosh L., Johnstone H., Correlation of c-fos, p53, and PCNA expression with treatment outcome in osteosarcoma Journal of Surgical Oncology 2000 73 2 125 126
56. Pakos E. E., Ioannidis J. P. A., The association of P-glycoprotein with response to chemotherapy and clinical outcome in patients with osteosarcoma. A meta-analysis Cancer 2003 98 3 581 589
57. Scotlandi K., Serra M., Nicoletti G., Multidrug resistance and malignancy in human osteosarcoma Cancer Research 1996 56 10 2434 2439
58. Trammell R. A., Johnson C. B., Barker J. R., Bell R. S., Allan D. G., Multidrug resistance-1 gene expression does not increase during tumor progression in the MGH-OGS murine osteosarcoma tumor model Journal of Orthopaedic Research 2000 18 3 449 455
59. Hornicek F. J., Gebhardt M. C., Wolfe M. W., P-glycoprotein levels predict poor outcome in patients with osteosarcoma Clinical Orthopaedics Related Research 2000 373 11 17
60. Baldini N., Scotlandi K., Serra M., P-glycoprotein expression in osteosarcoma: a basis for risk-adapted adjuvant chemotherapy Journal of Orthopaedic Research 1999 17 5 629 632
61. Shnyder S. D., Hayes A. J., Pringle J., Archer C. W., P-glycoprotein and metallothionein expression and resistance to chemotherapy in osteosarcoma British Journal of Cancer 1998 78 6 757 759
62. Kandel R. A., Campbell S., Noble-Topham S. E., Bell R., Andrulis I. L., Correlation of P-glycoprotein detection by immunohistochemistry with mdr-l mRNA levels in osteosarcomas. Pilot study Diagnostic Molecular Pathology 1995 4 1 59 65
63. Wunder J. S., Bull S. B., Aneliunas V., MDR1 gene expression and outcome in osteosarcoma: a prospective, multicenter study Journal of Clinical Oncology 2000 18 14 2685 2694
64. Kaya M., Wada T., Akatsuka T., Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis Clinical Cancer Research 2000 6 2 572 577
65. Handa A., Tokunaga T., Tsuchida T., Neuropilin-2 expression affects the increased vascularization and is a prognostic factor in osteosarcoma International Journal of Oncology 2000 17 2 291 295
66. Coomber B. L., Denton J., Sylvestre A., Kruth S., Blood vessel density in canine osteosarcoma Canadian Journal of Veterinary Research 1998 62 3 199 204
67. Mori S., Ueda T., Kuratsu S., Hosono N., Izawa K., Uchida A., Suppression of pulmonary metastasis by angiogenesis inhibitor TNP-470 in murine osteosarcoma International Journal of Cancer 1995 61 1 148 152
68. Morishita T., Mii Y., Miyauchi Y., Efficacy of the angiogenesis inhibitor O -(chloroacetyl-carbamoyl)fumagillol (AGM-1470) on osteosarcoma growth and lung metastasis in rats Japanese Journal of Clinical Oncology 1995 25 2 25 31
69. Harms D., New entities, concepts, and questions in childhood tumor pathology General Diagnostic Pathology 1995 141 1 1 14
70. OSullivan M., Budhraja V., Sadovsky Y., Pfeifer J. D., Tumor heterogeneity affects the precision of microarray analysis Diagnostic Molecular Pathology 2005 14 2 65 71
71. Lee P. D., Noble-Topham S. E., Bell R. S., Andrulis I. L., Quantitative analysis of multidrug resistance gene expression in human osteosarcomas British Journal of Cancer 1996 74 7 1046 1050